Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Sang Hyun Shin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2533-4491; OpenAlex author ID A5053510846, A5132844031. Sources: OpenAlex.

Their work

Papers
40 (first author 5, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
98
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 4 papers · 2020: 3 papers · 2021: 4 papers · 2022: 3 papers · 2023: 5 papers · 2024: 1 paper · 2025: 9 papers · 2026: 3 papers

Papers 40

  1. Familial Pancreatic Cancer at a Tertiary Referral Center: Incidence and Clinical Characteristics in Korea. Co-author DOI 10.1002/jhbp.70142↗
  2. Multivisceral resection for pancreatic ductal adenocarcinoma with adjacent organ invasion: a propensity score-matched analysis. Last author DOI 10.1016/j.gassur.2026.102412↗
  3. Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cancer after curative surgery-toward future u… Co-author DOI 10.4174/astr.2026.110.2.76↗
  4. Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2025.1999↗
  5. Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. Co-author DOI 10.1002/jcsm.13643↗
  6. Synthetic data generation method improves risk prediction model for early tumor recurrence after surgery in patients with pancreatic cancer. Co-author DOI 10.1038/s41598-025-15800-4↗
  7. Implications of portal vein/superior mesenteric vein involvement in pancreatic cancer: A comprehensive correlation from preoperative radiological assessment to… Co-author DOI 10.1097/js9.0000000000002307↗
  8. The impact of distress at diagnosis in patients with pancreatic cancer undergoing pancreatectomy. Co-author DOI 10.1186/s12885-025-14365-9↗
  9. Prognostic Accuracy of ypTNM Stage in Patients with Pancreatic Cancer in the Era of Modern Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-024-16792-7↗
  10. Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Curative Surgery. Co-author DOI 10.1245/s10434-025-18029-7↗
  11. Impact of portal/superior mesenteric vein abutment angle on prognosis in pancreatic cancer: a single-center retrospective cohort study. Co-author DOI 10.4174/astr.2025.108.4.231↗
  12. Predicting prognosis and optimal timing for surgery using CA 19-9 in patients with pancreatic cancer who underwent FOLFIRINOX-based neoadjuvant therapy: a retr… Co-author DOI 10.4174/astr.2025.109.6.348↗
  13. Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.ctro.2024.100732↗
  14. Use of individualized 3D-printed models of pancreatic cancer to improve surgeons' anatomic understanding and surgical planning. Co-author DOI 10.1007/s00330-023-09756-0↗
  15. Prognosis of pancreaticoduodenectomy in octogenarians for pancreatic ductal adenocarcinoma with propensity score matched analysis. Last author DOI 10.1111/ans.18679↗
  16. Effects of cancer stigma on quality of life of patients with hepatobiliary and pancreatic cancer. Co-author DOI 10.14701/ahbps.22-084↗
  17. Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3390/biomedicines11082302↗
  18. Anti-cancer effects of metformin in a 3D co-culture model of pancreatic ductal adenocarcinoma. Co-author PMID 37293149↗
  19. Development of Nomograms for Predicting Prognosis of Pancreatic Cancer after Pancreatectomy: A Multicenter Study. Co-author DOI 10.3390/biomedicines10061341↗
  20. The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer. Last author DOI 10.3390/cancers14194556↗
  21. Pathological Response Predicts Survival after Pancreatectomy following Neoadjuvant FOLFIRINOX for Pancreatic Cancer. Last author DOI 10.3390/cancers15010294↗
  22. Appraisal of 5-year recurrence-free survival after surgery in pancreatic ductal adenocarcinoma. First author DOI 10.1002/jhbp.815↗
  23. Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Co-author DOI 10.1177/17588359211038478↗
  24. Upfront Surgery and Surgery Following Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma: A Comparative Analysis of Short-term Postoperative Outcomes. Co-author DOI 10.21873/anticanres.15386↗
  25. Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Resul… Co-author DOI 10.5009/gnl20306↗
  26. Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients. First author DOI 10.1097/md.0000000000022115↗
  27. Clinical outcomes of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma depending on preservation or resection of pylorus. First author DOI 10.14701/ahbps.2020.24.3.269↗
  28. Predictive Nomogram for Early Recurrence after Pancreatectomy in Resectable Pancreatic Cancer: Risk Classification Using Preoperative Clinicopathologic Factors. Last author DOI 10.3390/cancers12010137↗
  29. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Co-author DOI 10.1002/bjs.11144↗
  30. Validation of the eighth edition of the American Joint Committee on Cancer staging system and proposal of an improved staging system for pancreatic ductal aden… First author DOI 10.14701/ahbps.2019.23.1.46↗
  31. Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13206↗
  32. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Canc… First author DOI 10.3390/cancers11030278↗
  33. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Co-author DOI 10.1007/s10637-017-0497-1↗
  34. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Co-author DOI 10.1007/s10637-018-0598-5↗
  35. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients. Co-author DOI 10.1016/j.surg.2018.04.017↗
  36. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study. Co-author DOI 10.18632/oncotarget.14901↗
  37. Appraisal of Laparoscopic Distal Pancreatectomy for Left-Sided Pancreatic Cancer: A Large Volume Cohort Study of 152 Consecutive Patients. Co-author DOI 10.1371/journal.pone.0163266↗
  38. Can statistically determined prognostic factors predict the long-term survival of patients with pancreatic ductal adenocarcinoma following surgical resection?:… Co-author DOI 10.1097/mpa.0000000000000063↗
  39. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Co-author DOI 10.1097/mpa.0b013e31825b6ab0↗
  40. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally a… Co-author DOI 10.1016/j.surg.2012.03.010↗

Closest collaborators

The 25 strongest of 98 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. In Woong Han · 27 shared papers, 2020–2026 · strength 5.44
  2. Jin Seok Heo · 25 shared papers, 2020–2026 · strength 4.91
  3. Hongbeom Kim · 16 shared papers, 2021–2026 · strength 3.71
  4. So Jeong Yoon · 15 shared papers, 2021–2026 · strength 3.16
  5. Hochang Chae · 8 shared papers, 2025–2026 · strength 2.16
  6. Hyeong Seok Kim · 7 shared papers, 2025–2026 · strength 1.83
  7. Hye Jeong Jeong · 8 shared papers, 2022–2025 · strength 1.78
  8. Ji Hye Min · 5 shared papers, 2023–2025 · strength 1.03
  9. Dae Wook Hwang · 12 shared papers, 2016–2021 · strength 1.03
  10. Ki Byung Song · 12 shared papers, 2013–2020 · strength 0.90
  11. Song Cheol Kim · 12 shared papers, 2012–2020 · strength 0.83
  12. Jong Kyun Lee · 4 shared papers, 2022–2025 · strength 0.70
  13. Kyu Taek Lee · 4 shared papers, 2022–2025 · strength 0.70
  14. Joo Kyung Park · 4 shared papers, 2022–2025 · strength 0.70
  15. Joon Oh Park · 4 shared papers, 2021–2025 · strength 0.65
  16. Hyun Jeong Jeon · 3 shared papers, 2022–2023 · strength 0.55
  17. Sung Hyun Kim · 2 shared papers, 2025–2026 · strength 0.53
  18. Seung Soo Hong · 2 shared papers, 2025–2026 · strength 0.53
  19. Ho Kyoung Hwang · 2 shared papers, 2025–2026 · strength 0.53
  20. Chang Moo Kang · 2 shared papers, 2025–2026 · strength 0.53
  21. Hee Chul Park · 3 shared papers, 2022–2025 · strength 0.52
  22. Jeong Il Yu · 3 shared papers, 2022–2025 · strength 0.52
  23. Jung Yong Hong · 3 shared papers, 2021–2025 · strength 0.52
  24. Naru Kim · 3 shared papers, 2020–2023 · strength 0.45
  25. Jaewoo Kwon · 4 shared papers, 2019–2022 · strength 0.44

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.